Compare Stocks: BCYC, JANX, ANL, and GLUE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$15.09 -4.3%	$14.34	$0.88 ▼ $17.25	$971.77M	1.05	159,018 shs	77,002 shs
BCYC Bicycle Therapeutics	$3.38 -5.1%	$3.96	$3.33 ▼ $9.16	$236.58M	1.68	437,341 shs	728,668 shs
GLUE Monte Rosa Therapeutics	$10.50 -6.7%	$14.63	$7.24 ▼ $25.77	$895.79M	1.37	1.17 million shs	2.21 million shs
JANX Janux Therapeutics	$16.93 -0.2%	$17.18	$12.12 ▼ $35.34	$1.04B	2.4	880,117 shs	805,265 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	0.00%	-2.83%	+2.31%	+59.01%	+738.33%
BCYC Bicycle Therapeutics	0.00%	-8.15%	-20.28%	-22.30%	-59.42%
GLUE Monte Rosa Therapeutics	0.00%	-10.79%	-26.98%	-56.63%	+40.00%
JANX Janux Therapeutics	0.00%	+3.87%	-14.49%	+8.94%	-28.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$15.09 -4.3%	$14.34	$0.88 ▼ $17.25	$971.77M	1.05	159,018 shs	77,002 shs
BCYC Bicycle Therapeutics	$3.38 -5.1%	$3.96	$3.33 ▼ $9.16	$236.58M	1.68	437,341 shs	728,668 shs
GLUE Monte Rosa Therapeutics	$10.50 -6.7%	$14.63	$7.24 ▼ $25.77	$895.79M	1.37	1.17 million shs	2.21 million shs
JANX Janux Therapeutics	$16.93 -0.2%	$17.18	$12.12 ▼ $35.34	$1.04B	2.4	880,117 shs	805,265 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	0.00%	-2.83%	+2.31%	+59.01%	+738.33%
BCYC Bicycle Therapeutics	0.00%	-8.15%	-20.28%	-22.30%	-59.42%
GLUE Monte Rosa Therapeutics	0.00%	-10.79%	-26.98%	-56.63%	+40.00%
JANX Janux Therapeutics	0.00%	+3.87%	-14.49%	+8.94%	-28.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANL Adlai Nortye	2.71	Moderate Buy	$29.50	95.49% Upside
BCYC Bicycle Therapeutics	2.44	Hold	$13.86	309.97% Upside
GLUE Monte Rosa Therapeutics	2.90	Moderate Buy	$28.00	166.67% Upside
JANX Janux Therapeutics	2.67	Moderate Buy	$36.46	115.37% Upside

Current Analyst Ratings Breakdown

Latest BCYC, JANX, ANL, and GLUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/1/2026	GLUE Monte Rosa Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$25.00
10/1/2026	GLUE Monte Rosa Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/10/2026	ANL Adlai Nortye	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$31.00
9/9/2026	GLUE Monte Rosa Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
9/8/2026	ANL Adlai Nortye	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$49.00
9/8/2026	ANL Adlai Nortye	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/25/2026	GLUE Monte Rosa Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$28.00
8/24/2026	JANX Janux Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$23.00
8/24/2026	GLUE Monte Rosa Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	JANX Janux Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2026	GLUE Monte Rosa Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANL Adlai Nortye	$5M	194.36	N/A	N/A	($0.21) per share	-71.86
BCYC Bicycle Therapeutics	$72.86M	3.25	N/A	N/A	$8.79 per share	0.38
GLUE Monte Rosa Therapeutics	$123.67M	7.24	N/A	N/A	$3.58 per share	2.93
JANX Janux Therapeutics	$10M	103.51	N/A	N/A	$15.91 per share	1.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANL Adlai Nortye	-$35.53M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	-$218.96M	-$2.73	N/A	N/A	N/A	-311.11%	-33.22%	-27.79%	10/29/2026 (Estimated)
GLUE Monte Rosa Therapeutics	-$38.63M	-$1.76	N/A	N/A	N/A	-560.85%	-43.31%	-27.59%	11/5/2026 (Estimated)
JANX Janux Therapeutics	-$113.62M	-$1.64	N/A	N/A	N/A	N/A	-11.89%	-11.13%	11/5/2026 (Estimated)

Latest BCYC, JANX, ANL, and GLUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q3 2026	BCYC Bicycle Therapeutics	-$0.3990	N/A	N/A	N/A	$12.22 million	N/A
8/6/2026	Q2 2026	GLUE Monte Rosa Therapeutics	-$0.3805	-$0.43	-$0.0495	-$0.43	$12.91 million	$8.97 million
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.2513	-$0.35	-$0.0987	-$0.35	$19.08 million	$10.27 million
7/30/2026	Q2 2026	BCYC Bicycle Therapeutics	-$0.5756	-$0.72	-$0.1444	-$0.72	$4.22 million	$0.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANL Adlai Nortye	0.04	9.55	N/A
BCYC Bicycle Therapeutics	N/A	12.08	12.08
GLUE Monte Rosa Therapeutics	N/A	10.58	10.58
JANX Janux Therapeutics	N/A	16.35	16.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANL Adlai Nortye	35.21%
BCYC Bicycle Therapeutics	86.15%
GLUE Monte Rosa Therapeutics	79.96%
JANX Janux Therapeutics	75.39%

Insider Ownership

Company	Insider Ownership
ANL Adlai Nortye	N/A
BCYC Bicycle Therapeutics	22.00%
GLUE Monte Rosa Therapeutics	6.40%
JANX Janux Therapeutics	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANL Adlai Nortye	109	64.40 million	N/A	Not Optionable
BCYC Bicycle Therapeutics	288	69.99 million	54.60 million	Optionable
GLUE Monte Rosa Therapeutics	173	85.31 million	79.85 million	Optionable
JANX Janux Therapeutics	113	61.14 million	56.31 million	Optionable

BCYC, JANX, ANL, and GLUE Headlines

Recent News About These Companies

Is Janux’s Dual JANX013–JANX007 Trial Advancing a Durable Precision Oncology Platform for JANX?

September 29, 2026 | finance.yahoo.com

Janux Therapeutics (JANX) Advances Prostate Cancer Trial While Valuation Still Looks Pricey

September 27, 2026 | finance.yahoo.com

Analyzing Agenus (NASDAQ:AGEN) & Janux Therapeutics (NASDAQ:JANX)

September 27, 2026 | americanbankingnews.com

910,460 Shares of Janux Therapeutics, Inc. $JANX Purchased by Bank of America Corp DE

September 26, 2026 | marketbeat.com

State Street Corp Boosts Stake in Janux Therapeutics, Inc. $JANX

September 25, 2026 | marketbeat.com

Janux Therapeutics: It's Too Early To Tell If Prostate Cancer Program Can Succeed

September 18, 2026 | seekingalpha.com

Janux Therapeutics, Inc. (JANX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow

September 17, 2026 | seekingalpha.com

4 Prostate Cancer Drug Stocks to Watch During Awareness Month

September 15, 2026 | zacks.com

Janux Therapeutics Doses First Participant in Phase 1 Study of Prostate Cancer Candidate

September 14, 2026 | finance.yahoo.com

Janux Therapeutics Doses First Patient In Phase 1 Study Of JANX013

September 14, 2026 | rttnews.com

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

September 14, 2026 | finance.yahoo.com

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

September 14, 2026 | businesswire.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 14, 2026 | marketbeat.com

Squarepoint Ops LLC Has $8.18 Million Holdings in Janux Therapeutics, Inc. $JANX

September 11, 2026 | marketbeat.com

Janux Therapeutics (NASDAQ:JANX) Stock Price Down 7.2% - Here's What Happened

September 10, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $2.08 Million in Janux Therapeutics, Inc. $JANX

September 8, 2026 | marketbeat.com

Wellington Management Group LLP Sells 90,290 Shares of Janux Therapeutics, Inc. $JANX

September 6, 2026 | marketbeat.com

JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know

August 21, 2026 | zacks.com

Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA)

August 14, 2026 | theglobeandmail.com

Analysts’ Top Healthcare Picks: Lyell Immunopharma (LYEL), Janux Therapeutics Inc (JANX)

August 13, 2026 | theglobeandmail.com

Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)

August 13, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BCYC, JANX, ANL, and GLUE Company Descriptions

Adlai Nortye NASDAQ:ANL

$15.09 -0.67 (-4.25%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$15.06 -0.04 (-0.23%)

As of 10/2/2026 07:30 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Bicycle Therapeutics NASDAQ:BCYC

$3.38 -0.18 (-5.06%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.38 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Monte Rosa Therapeutics NASDAQ:GLUE

$10.50 -0.76 (-6.75%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$10.55 +0.05 (+0.46%)

As of 10/2/2026 07:56 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Janux Therapeutics NASDAQ:JANX

$16.93 -0.03 (-0.18%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$16.94 +0.02 (+0.09%)

As of 10/2/2026 07:30 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCYC, JANX, ANL, and GLUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCYC, JANX, ANL, and GLUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCYC, JANX, ANL, and GLUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BCYC, JANX, ANL, and GLUE Company Descriptions

Adlai Nortye NASDAQ:ANL

Bicycle Therapeutics NASDAQ:BCYC

Monte Rosa Therapeutics NASDAQ:GLUE

Janux Therapeutics NASDAQ:JANX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCYC, JANX, ANL, and GLUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCYC, JANX, ANL, and GLUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCYC, JANX, ANL, and GLUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BCYC, JANX, ANL, and GLUE Company Descriptions

Adlai Nortye NASDAQ:ANL

Bicycle Therapeutics NASDAQ:BCYC

Monte Rosa Therapeutics NASDAQ:GLUE

Janux Therapeutics NASDAQ:JANX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools